Abstract
In China, around 23% of physicians (41% male, 3% female) currently smoke. Pharmacotherapy for tobacco dependence is available, but is not widely used in China. The purpose of this study was to estimate the effectiveness and the safety on smoking cessation of nicotine gum and nicotine patch in Chinese healthcare professionals. Three hundred regular smokers motivated to quit were recruited from six hospitals in China. All subjects were accepted nicotine replacement therapy, and they could choose nicotine gum (2 mg or 4 mg, depending on baseline smoking level) or nicotine patch (15 mg/16 h) for 12 weeks, with a 12-week follow-up. Limited behavioural support was provided. At Week 24, the 2-24 weeks continuous abstinence rate (verified by expired carbon monoxide) was 17%, the point prevalence abstinence rate (no smoking since the previous visit) was 35%, and 38% of subjects had continuously reduced their daily cigarette consumption by at least 50% versus baseline. Compliance with treatment was good, particularly with patch. No serious adverse event was reported, and most adverse events were mild or moderate. The most common treatment-related adverse events were gastrointestinal (both gum and patch) and local irritation symptoms. Nicotine patch and gum were well tolerated in Chinese smokers. Abstinence rates were comparable to those previously reported with nicotine replacement therapy, and many smokers who did not quit substantially reduced their cigarette consumption.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Li Q, Hsia J, Yang G. Prevalence of smoking in China in 2010. N Engl J Med 2011; 364(25): 2469–2470
Chinese Center for Disease Control and Prevention. Global adult tobacco survey (GATS) China country report. Beijing: Chinese Center for Disease Control and Prevention, 2011
World Health Organization. World Health Organization Report on the Global Tobacco Epidemic, 2008. The MPOWER package. Geneva: World Health Organization, 2008
Ceraso M, McElroy JA, Kuang X, Vila PM, Du X, Lu L, Ren H, Qian N, Jorenby DE, Fiore MC. Smoking, barriers to quitting, and smoking-related knowledge, attitudes, and patient practices among male physicians in China. Prev Chronic Dis 2009; 6(1): A06
Jiang Y, Ong MK, Tong EK, Yang Y, Nan Y, Gan Q, Hu TW. Chinese physicians and their smoking knowledge, attitudes, and practices. Am J Prev Med 2007; 33(1): 15–22
Hsueh KC, Chen CY, Yang YH, Huang CL. Smoking cessation program in outpatient clinics of Family Medicine Department in Taiwan: a longitudinal evaluation. Eval Health Prof 2010; 33(1): 12–25
Lam TH, Abdullah ASM, Chan SS, Hedley AJ; Hong Kong Council on Smoking and Health Smoking Cessation Health Centre (SCHC) Steering Group. Adherence to nicotine replacement therapy versus quitting smoking among Chinese smokers: a preliminary investigation. Psychopharmacology (Berl) 2005; 177 (4): 400–408
Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008; (1): CD000146
Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict 1991; 86(9): 1119–1127
Fiore MC, Jaén CR, Baker TB, et al.Guideline Panel. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service, 2008
Wennike P, Danielsson T, Landfeldt B, Westin A, Tønnesen P. Smoking reduction promotes smoking cessation: results from a double blind, randomized, placebo-controlled trial of nicotine gum with 2-year follow-up. Addiction 2003; 98(10): 1395–1402
Batra A, Klingler K, Landfeldt B, Friederich HM, Westin A, Danielsson T. Smoking reduction treatment with 4-mg nicotine gum: a double-blind, randomized, placebo-controlled study. Clin Pharmacol Ther 2005; 78(6): 689–696
Wang D, Connock M, Barton P, Fry-Smith A, Aveyard P, Moore D. ‘Cut down to quit’ with nicotine replacement therapies in smoking cessation: a systematic review of effectiveness and economic analysis. Health Technol Assess 2008; 12(2): iii–iv, ix–xi, 1–135
Malaiyandi V, Sellers EM, Tyndale RF. Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clin Pharmacol Ther 2005; 77(3): 145–158
Raunio H, Rautio A, Gullstén H, Pelkonen O. Polymorphisms of CYP2A6 and its practical consequences. Br J Clin Pharmacol 2001; 52(4): 357–363
Ossip DJ, Abrams SM, Mahoney MC, Sall D, Cummings KM. Adverse effects with use of nicotine replacement therapy among quitline clients. Nicotine Tob Res 2009; 11(4): 408–417
Greenland S, Satterfield MH, Lanes SF. A meta-analysis to assess the incidence of adverse effects associated with the transdermal nicotine patch. Drug Saf 1998; 18(4): 297–308
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Xiao, D., Zhong, N., Bai, C. et al. Nicotine gum or patch treatment for smoking cessation and smoking reduction: a multi-centre study in Chinese physicians. Front. Med. 8, 84–90 (2014). https://doi.org/10.1007/s11684-014-0311-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11684-014-0311-9